Nykode initiates clinical study of "pan-variant" Covid-19 vaccine

Nykode Therapeutics has initiated a clinical trial of its Covid-19 vaccine candidate, which is designed to fight emerging variants like Omicron by targeting T cells. "It's our objective to create a real pan-variant vaccine," says CEO Michael Engsig.

Michael Engsig, CEO of Nykode Therapeutics | Photo: Nykode Therapeutics / PR

Norwegian biotech firm Nykode Therapeutics, formerly known as Vaccibody, has dosed the first patient in a phase I/II trial involving its T-cell focused vaccine candidate, dubbed VB-D-01, designed to address new Covid-19 variants including Omicron, which are cause for concern the world over.

"It's our objective to create a real pan-variant vaccine that can be used as a universal booster, affecting both current and future variants," Nykode Therapeutic's Danish CEO, Michael Engsig, tells MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs